Issue 7: 10 February 2025 | Mpox: Transparency and Accountability for the Global Response

Issue 7: 10 February 2025 | Mpox: Transparency and Accountability for the Global Response

Our Reports
Welcome to the seventh issue of our report, “Mpox: Transparency and Accountability for the Global Response.” In this edition, we provide a comprehensive update on the latest developments and insights across all topic areas, featuring our most recent analyses and findings since the last issue. This report will be updated and shared every other week with our community. Latest updates at a glance: On January 27, the UK Health Security Agency (UKHSA) confirmed a new case of Clade Ib mpox, bringing the total number of cases in England since October 2024 to eight. Uganda began an mpox vaccination campaign on February 1st, after receiving 10,000 vaccine doses. The armed conflict in Goma has led to disruptions in sample collection, transportation, and confirmation in the region. A steep decline in mpox case…
Read More
Issue 6: 23 January 2025 | Mpox: Transparency and Accountability for the Global Response

Issue 6: 23 January 2025 | Mpox: Transparency and Accountability for the Global Response

Our Reports
Welcome to the sixth issue of our report, “Mpox: Transparency and Accountability for the Global Response.” In this edition, we provide a comprehensive update on the latest developments and insights across all topic areas, featuring our most recent analyses and findings since the last issue. This report will be updated and shared every other week with our community. Latest updates at a glance: The first patients have been enrolled in the MOSA trial in the DRC. This trial will evaluate different antivirals, starting with evaluating the safety and efficacy of brincidofovir (Emergent BioSolutions). Sierra Leone has reported its first 2 mpox cases in the country, and becomes the 21st country in Africa to report a case of mpox. The U.S. CDC has donated 300 mpox tests to Sierra Leone to help…
Read More
Issue 5: 10 January 2025 | Mpox: Transparency and Accountability for the Global Response

Issue 5: 10 January 2025 | Mpox: Transparency and Accountability for the Global Response

Our Reports
Welcome to the fifth issue of our report, “Mpox: Transparency and Accountability for the Global Response.” In this edition, we provide a comprehensive update on the latest developments and insights across all topic areas, featuring our most recent analyses and findings since the last issue. This report will be updated and shared every other week with our community. As always, we aim to serve as an external, independent source for tracking and catalyzing effective actions to meet and increase commitments, and to hold the key stakeholders to account for achieving emergency preparedness and response goals. Access the full report.
Read More
Issue 4: 12 December 2024 | Mpox: Transparency and Accountability for the Global Response

Issue 4: 12 December 2024 | Mpox: Transparency and Accountability for the Global Response

Our Reports
Welcome to the fourth issue of our biweekly report, “Mpox: Transparency and Accountability for the Global Response.” In this edition, we provide a comprehensive update on the latest developments and insights across all topic areas, featuring our most recent analyses and findings since the last issue. This report will be updated and shared every other week with our community. As always, we aim to serve as an external, independent source for tracking and catalyzing effective actions to meet and increase commitments, and to hold the key stakeholders to account for achieving emergency preparedness and response goals. Access the full report.
Read More
Issue 3: 22 November 2024 | Mpox: Transparency and Accountability for the Global Response

Issue 3: 22 November 2024 | Mpox: Transparency and Accountability for the Global Response

Our Reports
Welcome to the third issue of our biweekly report, “Mpox: Transparency and Accountability for the Global Response.” In this edition, we provide a comprehensive update on the latest developments and insights across all topic areas, featuring our most recent analyses and findings since the last issue. This report will be updated and shared every other week with our community. As always, we aim to serve as an external, independent source for tracking and catalyzing effective actions to meet and increase commitments, and to hold the key stakeholders to account for achieving emergency preparedness and response goals. Access the full report.
Read More
Issue 2: 7 November 2024 | Tracking and Analyzing Medical Countermeasures for Emerging Health Challenges: Mpox

Issue 2: 7 November 2024 | Tracking and Analyzing Medical Countermeasures for Emerging Health Challenges: Mpox

Our Reports
Welcome to the second issue of our biweekly report, "Tracking and Analyzing Medical Countermeasures for Emerging Health Challenges: Mpox." In this edition, we provide a comprehensive update on the latest developments and insights across all topic areas, featuring our most recent analyses and findings since the last issue. This report will be updated and shared every other week with our community. As always, we aim to serve as an external, independent source for tracking and catalyzing effective actions to meet and increase commitments, and to hold the key stakeholders to account for achieving emergency preparedness and response goals. Access the full report.
Read More
Tracking and Analyzing Medical Countermeasures for Emerging Health Challenges: Mpox

Tracking and Analyzing Medical Countermeasures for Emerging Health Challenges: Mpox

Our Reports
The COVID-19 pandemic exposed significant global inequities in the access to therapeutics, vaccines, testing, and other medical interventions that could limit the range and impact of the disease. These global inequities are not limited to the COVID-19 pandemic and need to be critically addressed in the ongoing mpox outbreak. Through Quickstart, we aim to serve as an external, independent source for tracking actions to meet commitments, catalyzing additional commitments to meet the need, and holding the world to account for the mpox response. Access the full report.
Read More

Experiences, Enablers, and Challenges in Service Delivery and Integration of COVID-19 Vaccines: a Rapid Systematic Review

Our Reports
Abstract: The COVID-19 vaccination is a crucial public health intervention for controlling the spread and severity of the SARS-CoV2 virus. COVID-19 vaccines have been developed in record time, but their deployment has varied across countries, owing to differences in health system capacity, demand for the vaccine, and purchasing power of countries. The aim of this rapid review is to summarize and synthesize experiences on COVID-19 vaccine service delivery and integration to inform future COVID-19 vaccination programming and contribute to the knowledge base for future pandemic management. a systematic search was conducted in PubMed, Scopus, and Global Index Medicus databases. Twenty-five studies were included in the analysis. Included studies spanned nine countries where COVID-19 vaccines were delivered through mass, mobile, and fixed-post vaccination service delivery models. There was limited evidence of…
Read More
COVID GAP Accountability Report, Issue 24

COVID GAP Accountability Report, Issue 24

Our Reports
April 19, 2023: COVID GAP Accountability Report Issue 24 Key Changes and Insights Since Previous Report: On April 17th, India reported over 9,000 new COVID-19 cases prompting some parts of the country to reintroduce mask mandates. The XBB.1.16 variant now accounts for roughly 7.2% of sequenced COVID-19 cases in the United States. The World Health Organization’s technical advisory group on COVID vaccine composition met in March to review the performance of updated COVID-19 vaccines. The group released a statement saying that the updated vaccines that contain either BA.1 or BA.4/5 provide better protection than vaccines that contain only the original virus. The FDA authorized a second bivalent COVID-19 vaccine for seniors ages 65+ and those with compromised immune systems. The Duke Global Health Innovation Center is a proud partner of the COVID…
Read More
COVID GAP Accountability Report, Issue 23

COVID GAP Accountability Report, Issue 23

Our Reports
April 5, 2023: COVID GAP Accountability Report Issue 23 Key Changes and Insights Since Previous Report: India reported over 3,600 new COVID-19 cases on April 3rd. This represents the largest single day increase in new cases in over 6 months. The World Health Organization is monitoring the XBB.1.16 subvariant that is currently circulating in India. The European Medicines Agency (EMA) and the Committee for Medicinal Products for Human Use (CHMP) have authorized the use of Bimervax as a COVID-19 booster vaccine. Bimervax is a bivalent, recombinant protein vaccine. South Korea plans to start using wastewater surveillance to monitor the spread of COVID-19 in the country. The health systems and response pillar of ACT-A has received $10 million in additional funding, and is now 35.9% funded. Botswana has achieved 70% vaccination…
Read More